arrow
M

Melvin Lafeber

Erasmus MC Transplant Institute
H指数:15
被引数:1,054

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

New insights into statin-intolerance: biopsychosocial differences, medication beliefs, trust in healthcare, and treatment decisions in statin-intolerant vs. statin-tolerant patients

他汀不耐受的新见解:他汀不耐受患者与他汀耐受患者在生物心理社会差异、药物信念、对医疗保健的信任以及治疗决策方面的比较

2026-08-180
OAAI
Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination

单价XBB.1.5疫苗接种优先增强SARS-CoV-2 Omicron谱系特异性免疫反应

2026-01-080
OAAI
Differences in antihypertensive drug blood levels in patients with hypertension (DECISION): a prospective study comparing pharmacokinetics and pharmacodynamics of perindopril in younger and older patients

高血压患者抗高血压药物血药浓度差异(DECISION研究):一项比较培哚普利在年轻和老年患者中药物动力学和药物动力学的前瞻性研究

2025-12-310
PRE
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study

甘油三酯丰富脂蛋白鞘脂在原发性高血压中发生改变:一项初步病例对照研究

2025-03-260
OAAI
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

原始新型冠状病毒肺炎启动方案影响二价BA.1和BA.5加强剂的免疫原性

2024-05-185
OAAI
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial
2023-08-0120
OAAI
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
2022-11-296
OAAI
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
2022-07-1510
OAAI
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Ad26.cov2.s引发后疫苗加强剂的免疫原性和反应原性

2022-03-1093
OAAI
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

异源ad26.cov2.s Prime和基于mRNA的加强新型冠状病毒肺炎疫苗接种方案: SWITCH试验方案

2021-09-2411
OAAI